



Autolus Therapeutics to host virtual event to discuss the company's obe-cel program in systemic lupus erythematosus

October 17, 2023 at 7:00 AM EDT

LONDON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will hold a virtual event on Tuesday, October 24, 2023 at 8:30 am ET, 1:30 pm BST, to discuss the company's CAR T strategy in autoimmune diseases and recent decision to advance obecabtagene autoleucel (obe-cel) into a Phase 1 study in systemic lupus erythematosus (SLE) in early 2024.

The event will include an introduction from Autolus's Chief Executive Officer, Dr Christian Itin, and presentations from key thought leader, Dr Maria Leandro, consultant rheumatologist at UCL Hospitals and senior lecturer at University College London, and company management.

Conference call participants should pre-register using this [link](#) to receive the dial-in numbers and a personal PIN, which are required to access the conference call. A simultaneous audio webcast and replay along with presentation materials will be accessible on the [events section](#) of Autolus's website.

Contact:

Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com

Susan A. Noonan
S.A. Noonan Communications
+1-917-513-5303
susan@sanoonan.com

Lauren Williams
Investase
+44 23 9438 7760
lauren@investase.com